New Imaging AI Tool Hits Market with Reimbursement Eligibility

Why It Matters

Reimbursement eligibility removes a key cost barrier, accelerating adoption of AI‑enhanced cardiovascular imaging and potentially improving patient risk stratification across hospitals.

Key Takeaways

• Elucid’s tool uniquely trained on histology for plaque analysis
• First FDA‑cleared AI plaque software with CPT 75577 reimbursement
• Quantifies lipid‑rich necrotic core and overall plaque burden
• Enables lesion‑level insights beyond aggregate plaque metrics
• Supports better treatment decisions for coronary and carotid disease

Pulse Analysis

Artificial intelligence is reshaping medical imaging, but widespread clinical uptake often stalls at the reimbursement hurdle. Elucid’s Lesion Inspection Tool bridges that gap by delivering histology‑validated plaque characterization, a capability previously limited to research settings. By integrating quantitative assessments of lipid‑rich necrotic core and overall plaque burden, the software equips interventional cardiologists and radiologists with granular data that can refine risk models and guide therapeutic choices.

The FDA’s clearance of Plaque‑IQ in late 2024 laid the regulatory groundwork, yet the real catalyst for market penetration arrived with the assignment of CPT code 75577. This code specifically covers AI‑driven quantification of coronary atherosclerotic plaque, allowing hospitals to bill insurers and recoup costs. Reimbursement transforms the tool from a premium add‑on into a financially viable component of routine cardiac imaging workflows, encouraging health systems to invest in the technology and train staff on its use.

Industry analysts see Elucid’s move as a bellwether for AI diagnostics in cardiovascular care. As insurers recognize the clinical value of precise plaque metrics, other vendors are likely to pursue similar histology‑based validation and seek CPT recognition. The competitive pressure could spur rapid innovation, lower prices, and broader integration of AI across imaging modalities. For providers, the combination of regulatory clearance, reimbursement, and actionable insights positions AI tools like Lesion Inspection as a strategic asset in improving outcomes and managing the growing burden of heart disease.